23 March 2018
News and Views
Links and Services
This month's Annals of Internal Medicine examines cost-effectiveness and budget impact of Hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States.
Sofosbuvir and ledipasvir, which have recently been approved for treatment of chronic hepatitis C
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors